Filter Search


Europe


Location Summary Deadline
Germany Conclusion Of Non-exclusive Discount Agreements Pursuant To Section 130a Paragraph 8/130c Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredient Acetylsalicylic Acid (b01ac06) Within The Framework Of A So-called Open-house Model. 2026-11-30
Germany Conclusion Of Non-exclusive Discount Agreements Pursuant To Section 130a Paragraph 8/130c Paragraph 1 Sgb V For Medicinal Products  2026-11-30
Germany Conclusion Of Non-exclusive Discount Agreements Pursuant To Section 130a Paragraph 8/130c Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredient Dornase Alfa (r05cb13) Within The Framework Of A So-called Open-house Model. 2026-11-30
Germany Abschluss Nicht Exklusiver Rabattverträge Gemäß §§ 130a Abs. 8/130c Abs. 1 Sgb V Zu Arzneimitteln Mit Dem Wirkstoff Acetylsalicylsäure (b01ac06) Im Rahmen Eines Sogenannten Open-house-modells. 2026-11-30
Germany Conclusion Of Non-exclusive Discount Agreements Pursuant To Section 130a Paragraph 8/130c Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredient Minoxidil (c02dc01) Within The Framework Of A So-called Open-house Model. 2026-11-30
Germany Medicines Containing The Active Ingredient Filgrastim (atc 2026-11-30
Germany Medicines Containing The Active Ingredient Secukinumab (atc 2026-11-30
Germany Medicines Containing The Active Ingredient Leuprorelin (atc 2026-11-30
Germany Medicines Containing The Active Ingredient Budesonide (atc 2026-11-30
Germany Conclusion Of Non-exclusive Discount Agreements Pursuant To Section 130a Paragraph 8/130c Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredient Peginterferon Beta-1a (l03ab13) Within The Framework Of A So-called Open-house Model. 2026-11-30
Whats app